Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy

Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer

(2022) Yinjie Gao et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels

(2022) Biagio Ricciuti et al.   JAMA Oncology

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

(2021) D.J. McGrail et al.   ANNALS OF ONCOLOGY

Racial and Ethnic Disparities in Clinical Trial Recruitment in the U.S.

(2021) Young-Rock Hong et al.   AMERICAN JOURNAL OF PREVENTIVE MEDICINE

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors

(2021) Leigh Marcus et al.   CLINICAL CANCER RESEARCH

Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project

(2021) D.M. Vega et al.   ANNALS OF ONCOLOGY

Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples

(2020) Joanne M. Mankor et al.   BRITISH JOURNAL OF CANCER

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project

(2020) Diana M Merino et al.   Journal for ImmunoTherapy of Cancer

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

(2020) Aurélien Marabelle et al.   LANCET ONCOLOGY

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Integrated genomic profiling expands clinical options for patients with cancer

(2019) Nike Beaubier et al.   NATURE BIOTECHNOLOGY

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

(2019) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

LBA79Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials

(2019) R S Herbst et al.   ANNALS OF ONCOLOGY

Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018

(2019) Jonathan M. Loree et al.   JAMA Oncology

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

(2017) Aaron M. Goodman et al.   MOLECULAR CANCER THERAPEUTICS

Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy

(2017) Mirjana Efremova et al.   Frontiers in Immunology